🏛️ Verified NIH Record • Updated 2025-11-10
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer (NCT04922307)
🔵 Active, Not Recruiting Observational / Diagnostic 🩺 Clinical Procedure Protocol Sponsor: Vanderbilt University Medical Center
🩺 Plain-English Summary (8th-Grade Level)
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
Who can join: Review the eligibility criteria below.
Location: H. Lee Moffitt Cancer Center — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
- Blood Sparing Protocol (PROCEDURE)
- Standard Blood Replacement (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- H. Lee Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute at Emory University — Atlanta, Georgia
- Vanderbilt University Medical Center — Nashville, Tennessee
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Cancer
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial — Houston, Texas
- Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma — Atlanta, Georgia
- CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition — New Brunswick, New Jersey
- NeoVax Plus Ipilimumab in Renal Cell Carcinoma — Boston, Massachusetts
- HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma — Bethesda, Maryland
- Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy — Chicago, Illinois
Explore by condition: All Kidney Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.